MX2022004157A - Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja. - Google Patents

Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja.

Info

Publication number
MX2022004157A
MX2022004157A MX2022004157A MX2022004157A MX2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A
Authority
MX
Mexico
Prior art keywords
patient
arterial pressure
mean arterial
hrs
map
Prior art date
Application number
MX2022004157A
Other languages
English (en)
Inventor
Khurram Jamil
Stephen Chris Pappas
Peter Teuber
Original Assignee
Mallinckrodt Hospital Products IP Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Hospital Products IP Unlimited Company filed Critical Mallinckrodt Hospital Products IP Unlimited Company
Publication of MX2022004157A publication Critical patent/MX2022004157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los principios y modalidades de la presente descripción se refieren a métodos para el aumento de la supervivencia de un paciente que tiene síndrome hepatorrenal tipo 1 (SHR-1) y presión arterial media (PAM) baja. Los métodos pueden incluir la identificación de un paciente que tiene SHR-1 que tiene una PAM de referencia de menos de 65 mmHg y la administración al paciente de una cantidad de terlipresina eficaz para tratar el SHR-1 en el paciente. En otros aspectos, el método puede incluir la administración de una dosis efectiva de terlipresina a un paciente en necesidad de la misma cada 6 horas por medio de inyección intravenosa (IV) en bolo durante 2 minutos, cuando la dosis sea suficiente para producir un aumento en la PAM y una disminución de la frecuencia cardíaca en el paciente. Es posible que el paciente no tenga sepsis evidente, choque séptico o infección no controlada.
MX2022004157A 2019-10-30 2020-10-29 Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja. MX2022004157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (1)

Publication Number Publication Date
MX2022004157A true MX2022004157A (es) 2022-07-19

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004157A MX2022004157A (es) 2019-10-30 2020-10-29 Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja.

Country Status (10)

Country Link
US (1) US20210128676A1 (es)
EP (1) EP4051310A1 (es)
JP (1) JP2023500654A (es)
KR (1) KR20220092868A (es)
CN (1) CN114980914A (es)
AU (1) AU2020373408A1 (es)
BR (1) BR112022006329A2 (es)
CA (1) CA3159575A1 (es)
MX (1) MX2022004157A (es)
WO (1) WO2021084483A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022288996A1 (en) * 2021-06-07 2023-11-30 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
HRP20220225T1 (hr) * 2014-10-24 2022-04-29 Mallinckrodt Pharmaceuticals Ireland Limited Terlipresin za liječenje hepatorenalnog sindroma tip 1

Also Published As

Publication number Publication date
CA3159575A1 (en) 2021-05-06
WO2021084483A1 (en) 2021-05-06
AU2020373408A1 (en) 2022-04-21
KR20220092868A (ko) 2022-07-04
CN114980914A (zh) 2022-08-30
JP2023500654A (ja) 2023-01-10
BR112022006329A2 (pt) 2022-08-16
US20210128676A1 (en) 2021-05-06
EP4051310A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
EP4233861A3 (en) Compositions for treatment of essential tremor
JP2017501154A5 (es)
MD3883606T3 (ro) Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
MX2022004157A (es) Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja.
Lee et al. The effect of dexmedetomidine on propofol injection pain
US7470666B2 (en) Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome
Tokumine et al. Tissue necrosis caused by extravasated propofol.
ATE85521T1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines arzneimittels zur therapeutischen behandlung von schockzustaenden.
CR20230190A (es) Compuesto degradante en un medicamento
Zhang et al. Intraoperative tumor lysis-induced fatal hyperkalemia
CN209951904U (zh) 一种可拆卸静脉壶
SU1123662A1 (ru) Способ профилактики послеоперационного тромбоза глубоких вен нижних конечностей
Minard et al. Thymoxyethyldiethylamine antagonism to circulatory effects of histamine in anesthetized and nonanesthetized dogs
UA117797C2 (uk) Спосіб лікування трофічних виразок при хронічній венозній недостатності
Lin et al. Corrigendum to “advances of techniques in deep regional blocks”
US3632765A (en) Treatment of shock
UA120886C2 (uk) Застосування 2-(5s-метил-2-оксо-4r-фенілпіролідин-1-іл)-ацетаміду у лікуванні припадків
Daklalah et al. Comparison between Hydroxyethyl starch and Ringers lactate preloading solutions in elective inguinal hernia repair under subarachnoid block anesthesia
JPWO2021084483A5 (es)
van Dyk ECCO2R case study
Zhang et al. Effects of ullnastatin on proinflammatory cytokines and oxygen free radicals during orthotopic liver transplantation
XU et al. Study on the effect of percutaneous low frequency electric stimulation on prevention of venous indwelling needle thrombosis in patients with coronary heart disease
Martinez et al. Dexmedetomidine for DBS in Spain: 7AP5-4
UA102764U (uk) Спосіб лікування гіповолемії у хірургічних хворих
Stewart et al. The dose-dependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia